GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDL Biotech AB (XSAT:IDL) » Definitions » Debt-to-Revenue

IDL Biotech AB (XSAT:IDL) Debt-to-Revenue : 0.20 (As of Jun. 2021)


View and export this data going back to 2004. Start your Free Trial

What is IDL Biotech AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

IDL Biotech AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was kr1.95 Mil. IDL Biotech AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was kr3.04 Mil. IDL Biotech AB's annualized Revenue for the quarter that ended in Jun. 2021 was kr25.31 Mil. IDL Biotech AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2021 was 0.20.


IDL Biotech AB Debt-to-Revenue Historical Data

The historical data trend for IDL Biotech AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDL Biotech AB Debt-to-Revenue Chart

IDL Biotech AB Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 - 0.27 0.27

IDL Biotech AB Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.27 0.29 0.20

Competitive Comparison of IDL Biotech AB's Debt-to-Revenue

For the Diagnostics & Research subindustry, IDL Biotech AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDL Biotech AB's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDL Biotech AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where IDL Biotech AB's Debt-to-Revenue falls into.



IDL Biotech AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

IDL Biotech AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.925 + 4.024) / 21.748
=0.27

IDL Biotech AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.953 + 3.04) / 25.312
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2021) Revenue data.


IDL Biotech AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of IDL Biotech AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IDL Biotech AB (XSAT:IDL) Business Description

Traded in Other Exchanges
N/A
Address
Karlsbodavagen 39, Stockholm, SWE
IDL Biotech AB develops, produces and markets In Vitro Diagnostic tests for the health care sector. It offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. The company's trademark products includes TUBEX, TPS, UBC, MonoTotal and TPAcyk.

IDL Biotech AB (XSAT:IDL) Headlines

No Headlines